These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25142257)

  • 1. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.
    Mulgaonkar S; Kaufman DB
    Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belatacept: a new biologic and its role in kidney transplantation.
    Su VC; Harrison J; Rogers C; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
    Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
    Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.
    Arora S; Tangirala B; Osadchuk L; Sureshkumar KK
    Expert Opin Biol Ther; 2012 Jul; 12(7):965-79. PubMed ID: 22564126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction.
    LaMattina JC; Jason MP; Hanish SI; Ottmann SE; Klassen DK; Potosky D; Hutson WR; Barth RN
    Transplantation; 2014 Jan; 97(2):133-7. PubMed ID: 24342980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
    Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
    Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M; Van Der Giet M
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2010 Dec; 15(6):697-702. PubMed ID: 20930638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2.
    Wojciechowski D; Vincenti F
    Adv Chronic Kidney Dis; 2016 Sep; 23(5):306-311. PubMed ID: 27742385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
    Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.